Molecular Health to present at upcoming congresses
- Molecular Health will attend several upcoming conferences in Europe and the US
- Leading experts from the Company to present on AI in drug repurposing and evidence-driven decision support in research and clinical care
Molecular Health, a leading company in the field of data science for precision medicine and specializing in the development of products and services leveraging its proprietary biomedicine technology platform Dataome, is due to participate in several upcoming conferences between September and December, 2019. Company executives will give talks and participate in panel discussions on the use of artificial intelligence in the medical sector. The Company will present its product MH Predict, which assesses the likelihood of success of clinical trials. Moreover, it can be used for in silico-driven validation to identify drugs that can potentially be repurposed to treat other conditions. Further, Molecular Health will discuss its strategies for content curation in database generation and maintenance. Information on MH Guide, the company’s product to support physicians in selecting the optimal treatment for patients with cancer, will be available at several conferences. In addition, Dr. Friedrich von Bohlen, CEO of Molecular Health, will participate in a panel discussion on the fusion of medicine and artificial intelligence at ‘Wissenswerte’ in Bremen. Please see below for details on the presentations as well as conferences where Molecular Health will host booths and will be available to discuss the range of applications of Dataome.